710161Parenteral Formulation for New Class (DNA Minor Groove Binder) Anti-InfectiveClosedGRD Proof of ConceptInnovate UKMGB's preclinical candidate drug MGB BP3 is a potent anti-infective compound with high potency against Gram +ve bacteria, including life threatening highly resistant strains such as MRSA. The compound shows unusual physicochemical characteristics which make solubilisation very challenging As a result, MGB Biopharma has been forced to adopt an oral formulation to treat just a subset of bacterial infections - that of Clostridium difficile. The formulation for that indication was recently successfully shown to be superior to the gold standard drug (vancomycin) in the classic Hamster model. To be able to utilise this new class of drug against the most troublesome infectious diseases we need to extend the formulations in development to be able to successfully produce a reproducible and stable product capable of being given by the intravenous route to patients who are at risk of death due to resistant bacterial and other infections.